Quick Takeaways
- VANGUARD GROUP INC filed SCHEDULE 13G/A for Avalo Therapeutics Inc Common Stock (AVTX).
- Disclosed ownership: 4.4%.
- Date of event: 31 Dec 2025.
VANGUARD GROUP INC - 31 Dec 2025 SCHEDULE 13G/A Report for Avalo Therapeutics Inc Common Stock (AVTX)
- Filing Manager
- VANGUARD GROUP INC
- Reporting Manager
- The Vanguard Group
- Security
- Avalo Therapeutics Inc Common Stock
- Symbol
- AVTX
- Shares outstanding
- 18,150,880 shares
- Disclosed Ownership
- 804,084 shares
- Ownership
- 4.4%
- Form type
- SCHEDULE 13G/A
- Filing time
- 30 Jan 2026, 13:25:59 UTC
- Date of event
- 31 Dec 2025
- Previous filing
- 30 Oct 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"VANGUARD GROUP INC disclosed 4.4% ownership in Avalo Therapeutics Inc Common Stock (AVTX) on 31 Dec 2025."
What Changed
- Previous schedule filing date: 30 Oct 2025.
- Current filing was accepted on 30 Jan 2026, 13:25.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| The Vanguard Group | 4.4% | 804,084 | 0 | 92,039 | Ashley Grim | Head of Global Fund Administration |